Pre-poll Rate Rise Would Be A First The possibility of an interest rate rise smack in the middle of a federal election campaign and a momentous vote on the future of Australia’s second biggest retailer will dominate investors’ attention... Read Full Article Bank Role Casts Government As Heartless Debt Collectors By nationalising Northern Rock, Gordon Brown and Alistair Darling are indirectly setting themselves up in one of the most reviled and thankless of occupations - as debt collectors.... Read Full Article At Davos, The Squabble Resumes On How To Wire The Third World Passions still run high at the World Economic Forum over the best way to deploy computers in the developing world.... Read Full Article When Expectations And Exuberance Are Both Running High For Gustavo Dudamel watchers this concert with the New York Philharmonic was the debut that really mattered.... Read Full Article Hasbro, Electronic Arts Reach Digital Games Pact The companies said they have agreed to create electronic versions of Monopoly, Scrabble, Yahtzee and other games.... Read Full Article |
M.S. Drug Linked To Liver DamageWASHINGTON (AP) — Shares of two drug makers, Biogen Idec and the Elan Corporation, fell Wednesday after the companies reported that some patients had liver injuries after taking the drug Tysabri, a treatment for multiple sclerosis and Crohn’s disease. The companies issued a warning to doctors that signs of liver injury appeared in patients as early as six days after first taking Tysabri. Shares of Biogen Idec fell $1.40, to $60.13; Elan’s American depositary receipts fell $1.54, to $22.77, in trading on the New York Stock Exchange. The Food and Drug Administration posted the warning online and said patients with any signs of liver damage should stop taking the drug. Regulators updated the product’s labeling to highlight liver risks last month, when it was approved to treat the intestinal disorder Crohn’s disease. A spokeswoman for Biogen said the company had sent the letter to 2,500 doctors who prescribe the drug for multiple sclerosis and may not have seen the updated labeling. She said liver problems had been reported by fewer than one in 1,000 Tysabri patients. The drug posted sales of $343 million for Biogen last year. Tag CloudExternal InformationAdditional InformationSurgeon Accused of Speeding a Death to Get Organs...Faster, Higher, Stronger: A Swimmer’s Different Strokes for Success... Midnight Meals... Conclusions Are Reported on Teaching of Abstinence... Where Am I?News Main Page - Business - M.S. Drug Linked To Liver Damage |
i8news.com |